Compare IHS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHS | COGT |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.3B |
| IPO Year | 2021 | 2018 |
| Metric | IHS | COGT |
|---|---|---|
| Price | $7.52 | $39.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $9.32 | ★ $28.08 |
| AVG Volume (30 Days) | 1.0M | ★ 4.7M |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $1,765,825,000.00 | N/A |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | $5.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $3.72 |
| 52 Week High | $8.00 | $43.73 |
| Indicator | IHS | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 68.70 | 71.38 |
| Support Level | $6.93 | $38.10 |
| Resistance Level | $7.66 | $43.73 |
| Average True Range (ATR) | 0.24 | 2.22 |
| MACD | 0.10 | -0.53 |
| Stochastic Oscillator | 89.92 | 53.39 |
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.